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Abstract
Background: The description of  polymorphisms in many of  the key immunoregulatory molecules 
involved in the rejection process has offered a possible explanation for the individual variation in 
susceptibility to rejection and differences in allograft survival independent of  the many known 
contributory factors. The aim of  this work is to study the impact of  IL-10 cytokine gene polymorphism 
on renal transplant clinical course and outcome.
Methods: This work studied 50 transplant recipients maintained on sirolimus based immunosuppression 
for IL-10 cytokine gene polymorphisms. After transplantation patients were divided into two groups. 
Group (A) patients (12 patients) received sirolimus, tacrolimus and steroid, while Group (B) patients 
(38 patients) received sirolimus, mycophenolate mofetil and steroid. Results were correlated with acute 
and chronic rejection episodes as well as graft and patient outcome.
Results: In our study, we found no impact of  IL-10 on incidence and degree of  acute rejection episodes, 
incidence of  chronic allograft nephropathy, pathological changes in protocol biopsies, graft function 
and graft and patient survivals.  
Conclusion: From this work, we can conclude that the potential impact of  IL-10 cytokine gene 
polymorphisms on renal transplant clinical course and outcome have shown no influence, and probably 
other genes rather than IL-10 could be involved as key molecules for graft function.
Key words: IL-10, gene polymorphism, graft outcome, kidney transplantation, live-donor.
IntRoDUCtIon
The increasing success at preventing acute renal al-
lograft rejection has resulted in rejection rates of  less 
than 20% and one-year graft survivals of  more than 
90%.This success rate has led to focus on the im-
provement in long-term allograft survival, and the 
adjustment of  immunosuppression to the individual 
need. Currently, all patients are treated with broad-
spectrum immunosuppression with their myriad side 
effects. However, we do know that some patients 
may experience either discontinuation or substantial-
ly lower immunosuppression without suffering any 
ill effects (1). 
A possible explanation for the individual variation 
in rejection susceptibility and differences in allograft 
survival has been offered by the polymorphisms de-
scription of  immunoregulatory molecules involved in 
the rejection process. Several interesting observations 
have been made that would suggest that genetic vari-
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ability influencing allograft survival reaches beyond 
that of  the major histocompatibility complex (MHC) 
molecules. The influences of  polymorphisms in cy-
tokines, cytokine receptors, chemokines, adhesion 
molecules, and co-stimulatory molecules are among 
some of  those (2). 
The combination of  a high production of  TNF-α 
with low IL-10 production was associated with acute 
rejection in heart transplant patients, whereas high 
producers of  both TNF-α and IL-10 were associated 
with acute rejection in renal transplant patients (1). 
A functional role of  polymorphisms has also 
been implicated in the chronic rejection process (2). 
Polymorphisms in both interferon-γ (INF-γ) and 
transforming growth factor-β (TGF-β) have been 
associated with allograft fibrosis in lung transplant 
recipients. 
Two polymorphisms in the adhesion molecule in-
tercellular adhesion molecule-1(ICAM-1) have been 
associated with increased chronic renal allograft dys-
function (1), while one polymorphism in ICAM-1 
was found to have a protective effect with regard to 
chronic rejection in cardiac transplant recipients. 
These data are just some of  the increasing evi-
dence that there is a degree of  validity to the hypoth-
esis that polymorphisms in immunoregulatory mol-
ecules contribute to the heterogeneity in outcomes 
after transplantation (2).
 We aimed to examine the relationship between 
recipient cytokine genotype and clinical outcome 
in patients with a surviving allograft of  at least five 
years and to assess its sensitivity and specificity in 
predicting acute allograft rejection and chronic al-
lograft rejection.
Materials and methods
The material for this work comprised 50 recipients 
of  first renal transplants who were transplanted in 
the Mansoura Urology and Nephrology Center. Ex-
clusion criteria consisted of  prior transplantation, re-
cipients younger than 18 years, pre-transplant chem-
istries demonstrating a total cholesterol greater than 
300mg/dl, triglycerides greater than 400mg/dl, white 
blood cell count less than 4,000/mm3 or platelets less 
than 150,000/mm3  or change of  the basal immuno-
suppressive protocol for whatever reason.
Before kidney transplantation all patients were 
subjected to extensive clinical, laboratory, radiologi-
cal and immunological evaluation. After transplanta-
tion patients were prospectively randomised into two 
groups. Group (A) patients (12 patients) received 
sirolimus within 24 hours after completion of  sur-
gery in a dose of  10mg/day orally for three days, and 
then maintained on 5mg/day. Further doses were 
concentration controlled to keep 24-hour whole 
blood trough level between 6-12ng/ml. Tacrolimus 
was also administered to this group of  patients on 
the third day post-operative, provided that creati-
nine clearance was above 50ml/min. Tacrolimus was 
started at 0.03mg/kg/day in two divided doses. Fur-
ther doses were subsequently adjusted to maintain 
12-hour whole blood trough level of  3-7ng/ml (3). 
Group (B) patients (38 patients) received siroli-
mus and were maintained on a single oral morning 
dose of  10mg/day. Further doses were concentration 
controlled to keep 24-hour whole blood trough level 
between 10-15ng/ml. Mycophenolate mofetil 1gm 
twice a day was begun the morning after surgery. Pa-
tients remained on this dose unless side effects such 
as gastrointestinal toxicity or leucopenia necessitated 
dose reduction.
All patients in both groups were given basiliximab 
20mg intravenously at surgery and on day four post-
operative. Patients in both groups received intrave-
nous methyl prednisolone 500mg one day before and 
on day of  surgery. Oral prednisolone was then given 
at a dose of  1mg/kg/day which was then gradually 
tapered down to 0.1mg/kg by the 10th month post-
transplantation. 
Following kidney transplantation, all recipients 
were evaluated regarding graft function, tolerance to 
drugs, drug monitoring, radiological evaluations, his-
topathological examination of  the graft biopsy, and 
immunological screening.
In this work, renal allograft tissue histopathologic 
examination was carried out in cases of: delayed graft 
function, nephrotic range proteinuria, episodes of  
renal dysfunction (25% increase in creatinine from 
base line) unexplained by pre-renal, post-renal causes 
or high tacrolimus trough level in Group A patients, 
in addition to routine protocol core biopsy at one 
year post-transplantation that was carried out in 43 
patients in the study group.
Immunological screening
All the patients were investigated for gene polymor-
phism in IL-10 (at position -1082) as follows:
I. RNA isolation:
RNA isolation was performed using automated 
MagNA pure Lightcycler (LC) System and MagNA 
pure LC RNA Isolation Kit (Roche Applied Science, 
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Mannheim, Germany). Isolated RNAs were reverse 
transcribed and amplified using LC RNA Master 
Hybridization Probes Kit (Roche Applied Science, 
Mannheim, Germany) and PCR Master SYBR Green 
Kit (GeneCraft, Germany) according to the manu-
facturer’s instructions. 
II. Detection of cytokine polymorphisms of IL-10
(at position -1082):
Lightcycler RNA Master Hybridization Probes Kit 
(Roche molecular biochemicals, Mannheim, Germa-
ny) was used to determine the level of  IL-10. Real-
time PCR reaction using 20µL was performed with 
7.0µL RNA and 7.5µL enzyme mix in addition to 
0.5µM of  each primers and 0.25µM of  each probes. 
The forward primer was 5′-AGCTGAGAAC-
CAAGACCCAGA-3′ and the reverse primer was 5′- 
GGGCTGGGTCAGCTATCC-3′. Two hybridiza-
tion probes (Metabion, Germany) were designed to 
recognise adjacent internal sequences within the am-
plified fragment. One was labelled at the 5` end with 
LC Red 640, and phosphorylated at the 3` end to pre-
vent probe elongation by the Taq DNA polymerase. 
The other was labelled at the 3` end with fluorescine 
(Flu). The sequences of  the two probes were 5′- CG-
GCGCTGTCATCGATTTCTTCCCT-3′ Flu and LC 
Red 640-5′-TGAAAACAAGAGCAAGGCCGTG-
GAGC-3′. After 25 minutes incubation at 60oC for 
reverse transcription, a first denaturation step of  one 
minute at 95oC was started. Amplification was then 
performed for 45 cycles of  denaturation at 95oC for 
10s, annealing at 58oC for 15s, and extension at 72oC 
for 20s. Continuous fluorescence was monitored at 
the annealing step for each sample (4). Results were 
interpreted as follows: AA (Low producer), GA (In-
termediate producer) and GG (High producer) (4, 5 
and 6).
statistical analysis
Qualitative data were displayed in cross tabulations, 
and quantitative data were described in terms of  
arithmatic mean ± SD. Bivariate techniques were 
used for initial evaluation of  contrasts. Thus, the chi-
square and Fisher’s exact tests were used for com-
parisons of  frequencies of  qualitative variables; the 
Mann-Whitney test and the unpaired t-test were used 
for comparisons of  means of  two quantitative vari-
ables. A p-value <0.05 was considered significant. All 
analyses were carried out using the computer pack-
age SPSS for Windows, version 16.
Results
This work involved 38 male and 12 female patients 
with a mean age of  33.86 ± 9.79 years. These patients 
received their allografts from relatively young donors 
(mean = 34.38+10.42 years) who were related in 82% 
of  the cases. The duration of  pre-transplant hemo-
dialysis ranged from 0-48 months during which pe-
riod they received a mean of  3.11+2.89 blood units. 
The mean duration of  post-transplant follow up was 
72.48+6.28 months (range= 62-85) (Table 1).
table 1: Demographic and clinical characteristics of  
the 50 renal allograft recipients at commencement of  
the study
1. Recipient age 33.86 ± 9.79
(19-57)
M ± SD (range), years
2. Recipient gender 38/12
(76%) 
M/F1 (M %)
3. Donor age, M ± SD 34.38 + 10.42
(21-65)
(range), years
4. Donor gender 24/26
(48%)
M/F1 (M %)
5. Donor relation (% of  related) 41/9
(82%)
R/U2
6. Duration of  HD3 15.88 + 15.74
(0-48)
M ± SD (range), months
7. Number of  pre-transplant blood 3.11 + 2.89
(1-10)
M ± SD (range), units
8. Post-transplant follow-up 72.48 + 6.28
(62-85)
M ± SD (range), months
1: Male/Female
2: Related/Unrelated
3: Hemodialysis
Our data showed that there was no statistically 
significant difference between HLA and DR match-
ing, and sum of  HLA and DR in relation to incidence 
of  acute rejection (P. 0.613, 0.317 and 0.783 respec-
tively) or chronic allograft nephropathy (P. 0.565, P. 
0.268 and P. 0.129 respectively).
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Analysis of the data in relation to IL-10 
production The 50 patients included in this study 
were divided into three groups according to the level 
of IL-10 pro-duction {low (n=22), intermediate 
(n=15) and high (n=13)}.
The three groups of  renal allograft recipients 
were comparable with respect to donor age, donor 
gender, recipient age, recipient gender, original kid-
ney disease, donor relation and duration of  hemodi-
alysis (Table 2).
table 2: Demographic and clinical characteristics of  the 
50 renal allograft recipients in relation to IL-10 production
IL-10 production
P valueLow
(n=22)
Inter-
mediate
(n=15)
High
(n=13)
Age of  donor M 
+ SD (range), years
Sex of  donor
-Male
-Female
Age of  recipient M 
+ SD (range), years
Sex of  recipient
-Male
-Female
Original kidney 
disease
-Membranous GN1
-FSGS2
-Chronic pyelone-
phritis
-Nephrosclerosis
-ESRD3
-Hereditary
-Amyloidosis
-Stone kidney 
disease
-APCKD4
-Unknown
Consanguinity
-Parents
-Sibling
-Offspring
-Other relative
-Unrelated
Duration of  HD5  
(median), months
32.41 ± 
9.16
12
10
32.86 ± 
10.53
18
4
0
1
4
1
2
1
0
3
1
9
4
14
0
0
4
16.5
37.47 ± 
12.92
7
8
35.27 ± 
8.18
10
5
1
0
3
0
3
0
2
2
0
4
3
8
0
1
3
5
34.15 ± 
9.09
5
8
33.92 ± 
10.78
10
3
0
1
3
0
2
0
0
2
0
5
2
8
1
0
2
7
0.356
0.650
0.772
0.568
0.773
0.465
0.223
1: Glomerulonephritis
2: Focal Segmental Glomerulosclerosis
3: End-stage Renal Disease
4: Adult Polycystic Kidney Disease 
5: Hemodialysis
In our study, there was no statistically signifi-
cant difference between the three groups regarding 
the number of  acute rejection episodes, degree of  
the first attack of  acute rejection, and incidence of  
chronic allograft nephropathy. Only one recipient 
from the first group (low producers) suffered a sec-
ond attack of  acute cellular rejection (Table 3).
table 3: Relation between number, degree, management and 
response to therapy in acute rejection episodes; incidence 
of  chronic allograft nephropathy and IL-10 production
IL-10 production
P valueLow
(n=22)
Inter-
mediate
(n=15)
High
(n=13)
Number of  acute 
rejection episodes
- Zero
- One
- Two
Degree of  1st acute 
rejection
-ACR1grade 1
-BLR2
Management of  1st 
acute rejection
-Steroids
-Other therapy
Response of  1st 
acute rejection to 
therapy
-Complete re-
sponse
Degree of  2nd 
acute rejection
-ACR1grade 1
-BLR2
Management of  
2nd acute rejection
-Steroids
-Other therapy
Response of  2nd 
acute rejection to 
therapy
-Complete re-
sponse
Chronic allograft 
nephropathy
-No
-Yes
17
4
1
1
4
5
0
5
1
0
1
0
1
20
2
14
1
0
0
1
1
0
1
0
0
0
0
0
14
1
12
1
0
0
1
1
0
1
0
0
0
0
0
12
1
0.578
0.792
0.964
1: Acute Cellular Rejection
2: Border Line Rejection
Regarding the results of  the first biopsy, it 
showed no statistically significant difference between 
the three groups and according to Banff  classifica-
tion, all first biopsies showed Border Line Rejection 
{N.B. Those rejecters were all from the first group 
(low producers)}. Regarding the results of  the sec-
ond biopsy and the Banff  classification of  these bi-
opsies, there was no statistically significant difference 
between the three groups. Only two recipients were 
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subjected to a third graft biopsy (one from the first 
group {low producers} with its result as normal and 
the second one from the third group {high produc-
ers} who had chronic rejection). Forty-three recipi-
ents were subjected to protocol biopsy one year after 
transplantation with no statistically significant differ-
ence between the three groups regarding the results 
of  these protocol biopsies (Table 4).
table 4: Relation between results, Banff  classification of  
the graft biopsies; results of  protocol biopsies and IL-10 
production
IL-10 production
P valueLow
(n=22)
Inter-
mediate
(n=15)
High
(n=13)
Result of  1st 
biopsy
-Insufficient
-Normal
-ACR1
-Acute FK toxicity
Banff  classifica-
tion of  1st biopsy
- BLR2
-ACR1 grade 1
Result of  2nd 
biopsy
-ACR1
-Acute FK toxicity
Banff  classifica-
tion of  2nd  biopsy
-BLR2
-ACR1grade 1
Result of  3rd 
biopsy
-Normal
-Chronic rejection
Protocol biopsy
-Yes
-No
Result of  protocol 
biopsy
-Normal
-Chronic tubuloin-
terstitial
fibrosis (mild 
degree)
-Chronic tubuloin-
terstitial
fibrosis (moderate 
degree)
1
2
4
1
4
0
2
2
0
2
1
0
20
2
(n=20)
5
14
1
0
1
0
1
0
0
1
0
1
0
13
2
(n=13)
5
7
1
0
2
0
0
0
0
1
0
1
0
0
1
10
3
(n=10)
1
9
0
0.385
0.595
0.135
0.384
0.513
0.465
1: Acute Cellular Rejection
2: Border Line Rejection
Analysis of  MMF group (n=38) in relation to IL-
10 production showed no statistically significant dif-
ference between the three groups regarding the num-
ber of  acute rejection episodes, incidence of  chronic 
allograft nephropathy, incidence, degree and onset of  
proteinuria, or results of  protocol biopsies (Table 5).
table 5: Analysis of  MMF group in relation to IL-10 pro-
duction
IL-10 production
P valueLow
(n=18)
Inter-
mediate
(n=8)
High
(n=12)
Number of  acute 
rejections
-Zero
-One
-Two
Chronic allograft 
nephropathy
-Yes
-No
Proteinuria
   -No
   ->1gm/day for 
>6 months 
Degree of  pro-
teinuria
    -1-3gm/day
    ->3gm/day
Onset of  pro-
teinuria (median), 
months
Protocol biopsy
-Yes
-No
Result of  protocol 
biopsy
-Normal
-Chronic tubuloin-
terstitial
fibrosis (mild 
degree)
-Chronic tubuloin-
terstitial
fibrosis (moderate 
degree)
15
2
1
0
18
13
5
(n=5)
3
2
8
16
2
(n=16)
5
11
0
7
1
0
0
8
7
1
(n=1)
1
0
2
6
2
(n=6)
3
3
0
11
1
0
1
11
9
3
(n=3)
3
0
48
9
3
(n=9)
1
8
0
0.868
0.329
0.693
0.358
0.142
0.544
0.256
Analysis of  FK group (n=12) in relation to IL-2 
production also showed no statistically significant 
difference between the three groups regarding the 
number of  acute rejection episodes, incidence of  
chronic allograft nephropathy, incidence of  protein-
uria, or results of  protocol biopsies (Table 6).
Af
ric
an
 Jo
ur
na
l o
f 
N
ep
hr
ol
og
y 
| 
V
ol
um
e 
19
, N
o 
1,
 D
ec
em
be
r 
20
16
11
IL-10 Gene polymorphism and graft outcome in live-donor kidney transplantation
table 6: Analysis of  FK group in relation to IL-10 pro-
duction
IL-10 production
P valueLow
(n=4)
Interme-
diate
(n=7)
High
(n=1)
Number of  acute 
rejection
-Zero
-One
Chronic allograft 
nephropathy
-Yes
-No
Proteinuria
   -No
   ->1gm/day for 
>6 months 
Degree of  pro-
teinuria
    -1-3gm/day
    ->3gm/day
Onset of  pro-
teinuria (median), 
months
Protocol biopsy
-Yes
-No
Result of  protocol 
biopsy
-Normal
-Chronic tubuloin-
terstitial
fibrosis (mild 
degree)
-Chronic tubuloin-
terstitial
fibrosis (moderate 
degree)
2
2
2
2
4
0
0
4
0
0
3
1
7
0
1
6
6
1
(n=1)
1
0
4
7
0
2
4
1
1
0
0
1
1
0
0
1
0
0
1
0
0.091
0.351
0.677
0.719
All rejection episodes were managed and re-
sponded completely to pulse steroid therapy.
Lastly, the three groups were comparable regard-
ing the graft survival (P. 0.496) and the 50 patients 
who were included in this study were alive with func-
tioning grafts at the last follow-up.   
Discussion
Genetic variations including single nucleotide poly-
morphisms (SNPs), dinucleotide repeats and micro-
satellites have been identified in a number of  genes 
encoding cytokines, cytokine receptors, chemokines 
and their receptors, adhesion molecules. Several of  
the polymorphisms were located in the promoter re-
gion of  the gene, affect transcription and translation, 
and not infrequently determine the level of  expres-
sion of  the protein product. A wide variety of  dis-
ease states ranging from infection susceptibility and 
autoimmunity to hypertension have been associated 
with known sequence variations (7). 
IL-10 gene polymorphism and acute rejection
IL-10 is known to inhibit antigen-dependent prolif-
eration of T cells in vitro and to suppress responses 
in the primary mixed lymphocyte reaction (8), but 
appears to have paradoxical effects in organ trans-
plantation. Although elevated IL-10 gene expression 
has been associated with reduced rejection of heart 
and liver transplants (9 and 10), in kidney transplant 
recipients high IL-10 status has been associated with 
increased acute rejection (2 and 11).
While IL-10 polymorphisms have been reported 
to affect the risk of  rejection in several reports (12 
and 2), there are a number of  reports that have been 
unable to detect the influence of  IL-10 (13 and 14).
In our study, we did not find associations between 
IL-10 gene polymorphism and incidence or degree 
of  acute graft rejection. In contrast to our findings, 
many reports found an association between IL-10 
gene polymorphism and the risk of  rejection, al-
though some of  these reports have conflicting results 
regarding the association between the level of  IL-10 
production and the risk of  rejection.
The first group found that high producers of  IL-
10 have higher incidence of  rejection, like the study 
conducted by Sankaran and co-workers who studied 
115 renal allograft recipients, where all patients with 
primary function were given cyclosporine A (CsA) 
monotherapy. Transplant patients with delayed graft 
function were commenced on a triple therapy regi-
men of  CsA, prednisolone and azathioprine. When 
all patients were analysed independently of  HLA-
DR matching, no association was found between 
cytokine gene polymorphism and rejection episodes. 
However, the recipient IL-10 high producer geno-
type showed an association with increased rejection 
episodes only when the HLA-DR-mismatched trans-
plants were analysed separately (2).
The explanation was that IL-10 may enhance 
antibody responses against the graft as reported by 
Merville and co-workers in 1995 (15) and low IL-10 
responses can be used to predict a low risk for acute 
graft rejection (16).  Furthermore, IL-10 is a potent 
stimulator, inducing differentiation and proliferation 
of  B cells, thus driving the immune response towards 
the humoral pathway (17).
Also, Yang and Liu found that patients with acute 
Af
ric
an
 Jo
ur
na
l o
f 
N
ep
hr
ol
og
y 
| 
V
ol
um
e 
19
, N
o 
1,
 D
ec
em
be
r 
20
16
12
IL-10 Gene polymorphism and graft outcome in live-donor kidney transplantation
rejection have a higher IL-10 level than those without 
rejection. When HLA-DR mismatched, the recipient 
with IL-10 GG genotype (high producer) showed a 
higher occurrence of  acute rejection than those with 
low producer genotype in the first three months after 
renal transplantation (18).
On the other hand, the second group found that 
low producers of  IL-10 have higher incidence of  re-
jection. In a study conducted by George and others, 
they found that the frequency of  IL-10 (-1082) AA, 
a genotype associated with low production of  IL-10, 
was high in the rejection group (34 patients) when 
compared to a rejection-free group (71 patients), 
even in recipients with HLA-DR matched transplants 
(P=.01) (19). These results were consistent with the 
experimental work done, suggesting the dominant 
role of  IL-10 as an anti-inflammatory cytokine (20 
and 21). 
In 2007, Amirzargar and co-workers studied 100 
kidney transplant recipients who had at least one year 
of  post-transplantation follow-up. All recipients were 
prescribed cyclosporine or tacrolimus, azathiopurine 
or MMF, and methylprednisone treatment after trans-
plantation. They found that the low-producer IL-10 
genotype was higher in acute rejection episodes (22).
On the contrary, our results are in agreement with 
the findings reported by Marshall and co-workers 
who studied 22 polymorphisms in 11 cytokine and 
cytokine receptor genes (including IL-10) and found 
no association between any polymorphism and the 
incidence or severity of  acute rejection (23).
Lastly, Chen and co-workers in their study in 
2014, which included 325 renal transplant recipients, 
found no association between IL-10 genotype and 
incidence of  rejection or graft survival (24).
IL-10 gene polymorphism and chronic rejection A 
functional role of polymorphisms has also been 
implicated in the chronic rejection process (2).
In our study, there was no statistically significant 
difference between IL-10 production and the inci-
dence of  chronic rejection.
Similar results were published by Canossi and co-
workers in 2007 when they studied 86 renal transplant 
recipients. The average follow-up was 78 months af-
ter transplantation and all patients received cyclospo-
rine/prednisolone/azathioprine or mycophenolate 
mofetil. Only nine patients had chronic rejection. 
Canossi and co-workers failed to prove a significant 
relationship between IL-10 gene polymorphism and 
incidence of  chronic rejection (25).
On the contrary, Uboldi de Capei and his team 
studied 416 first cadaveric renal allograft recipients, 
and after 10 years post-transplantation, the graft was 
still functional in 171 patients (41%) – with 102 of  
these 171 patients also typed for cytokine polymor-
phisms by PCR-SSP. They found that patients who 
were high IL-10 producers and HLA Class I mis-
matched (but matched for Class II) were protected 
from chronic rejection {P=0.0008} (26). The ex-
planation suggested by them was that interferon-γ, 
which induces the expression of  MHC Class II mol-
ecules, is not inhibited by IL-10 (27). 
An association between IL-10 (-1082) SNP geno-
types and chronic rejection after kidney transplanta-
tion was investigated in another study that reported 
an association (which was not statistically significant) 
between the high IL-10 producer genotype (GG) 
and a better graft function five years post-transplant, 
whereas patient survival after one and five years was 
not associated with any IL-10 genotype (28).
IL-10 gene polymorphism, and graft and 
patient survival
Analysis of our data showed that there was no im-
pact of IL-10 production on either patient or graft 
survival. This can be explained by the comparable 
results in all groups regarding the incidence of both 
acute and chronic rejections.
In agreement with our findings, a very large study 
conducted by Mytilineos and co-workers who stud-
ied 4,199 renal transplant recipients (of  whom 2,298 
were first transplants and 1,901 were re-transplanted) 
from 73 transplant centres participating in the Col-
laborative Transplant Study. Caucasian patients who 
were transplanted between 1987 and 2000 were stud-
ied. They did not find an effect of  IL-10 gene poly-
morphisms on kidney graft survival (29).
On the other hand, Uboldi de Capei and col-
leagues who studied 102 renal allograft recipients 
found that in patients with grafts that maintain func-
tion for more than 10 years, survival of  patients with 
a functioning organ can be associated with the high 
IL-10 producer genotype (26).
Conclusion
Our study showed that there was no role for IL-10 
gene polymorphism on the incidence of  acute rejec-
tion, chronic rejection and patient and graft survival. 
However, the genetic polymorphisms examined in 
this study addressed only a fraction of  all cytokine 
genes involved in the immune response, and addi-
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tional studies are needed to be conducted to clearly 
explore the role of  cytokine gene polymorphism in 
renal transplantation outcome. 
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